• Western blot analysis of various cells using IGF-IR Polyclonal Antibody diluted at 1：2000
  • Western blot analysis of Hela cells using IGF-IR Polyclonal Antibody diluted at 1：2000
  • Immunohistochemical analysis of paraffin-embedded Mouse-testis tissue. 1, IGF-IR Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunohistochemical analysis of paraffin-embedded Mouse-kidney tissue. 1, IGF-IR Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunohistochemical analysis of paraffin-embedded Human-stomach-cancer tissue. 1, IGF-IR Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunohistochemical analysis of paraffin-embedded Rat-kidney tissue. 1, IGF-IR Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunohistochemical analysis of paraffin-embedded Human-liver tissue. 1, IGF-IR Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunofluorescence analysis of rat-kidney tissue. 1, IGF-IR Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunofluorescence analysis of mouse-kidney tissue. 1, IGF-IR Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunohistochemical analysis of paraffin-embedded Human-Tonsil tissue. 1, IGF-IR Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Immunofluorescence analysis of mouse-kidney tissue. 1, IGF-IR Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunofluorescence analysis of mouse-lung tissue. 1, IGF-IR Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunofluorescence analysis of mouse-lung tissue. 1, IGF-IR Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
  • Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using IGF1R Antibody. The picture on the right is blocked with the synthesized peptide.
  • Immunohistochemical analysis of paraffin-embedded Human-liver-cancer tissue. 1, IGF-IR Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room tempeRature, 30min). Negative control was used by secondary antibody only.
  • Western blot analysis of lysates from 293 cells, treated with Insulin, using IGF1R Antibody. The lane on the right is blocked with the synthesized peptide.
  • Immunofluorescence analysis of rat-kidney tissue. 1, IGF-IR Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).3, Picture B: DAPI (blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B

Anti-IGF-IR antibody (1126-1175 aa) (STJ93647)

SKU:
STJ93647

£46.00 - £226.00
Current Stock:
Host: Rabbit
Applications: IF/WB/IHC/ELISA
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Insulin-like growth factor 1 receptor and Insulin receptor (1126-1175 aa) is suitable for use in Immunofluorescence, Western Blot, Immunohistochemistry and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: IF 1:50-200
WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:10000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: INSR
IGF1R
Gene ID: 3643
3480
Uniprot ID: INSR_HUMAN
IGF1R_HUMAN
Immunogen Region: 1126-1175 aa
Specificity: IGF-IR Polyclonal Antibody detects endogenous levels of IGF-IR protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human IGF1R at the amino acid range 1126-1175
Post Translational Modifications Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Autophosphorylation occurs in a sequential manner.Tyr-1165 is predominantly phosphorylated first, followed by phosphorylation of Tyr-1161 and Tyr-1166. While every single phosphorylation increases kinase activity, all three tyrosine residues in the kinase activation loop (Tyr-1165, Tyr-1161 and Tyr-1166) have to be phosphorylated for optimal activity. Can be autophosphorylated at additional tyrosine residues (in vitro). Autophosphorylated is followed by phosphorylation of juxtamembrane tyrosines and C-terminal serines. Phosphorylation of Tyr-980 is required for IRS1- and SHC1-binding. Phosphorylation of Ser-1278 by GSK-3beta restrains kinase activity and promotes cell surface expression, it requires a priming phosphorylation at Ser-1282. Dephosphorylated by PTPN1. Polyubiquitinated at Lys-1168 and Lys-1171 through both 'Lys-48' and 'Lys-29' linkages, promoting receptor endocytosis and subsequent degradation by the proteasome. Ubiquitination is facilitated by pre-existing phosphorylation. Sumoylated with SUMO1. Controlled by regulated intramembrane proteolysis (RIP). Undergoes metalloprotease-dependent constitutive ectodomain shedding to produce a membrane-anchored 52 kDa C-Terminal fragment which is further processed by presenilin gamma-secretase to yield an intracellular 50 kDa fragment.
Function Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R. When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
Protein Name Insulin-Like Growth Factor 1 Receptor
Insulin-Like Growth Factor I Receptor
Igf-I Receptor
Cd Antigen Cd221 Cleaved Into - Insulin-Like Growth Factor 1 Receptor Alpha Chain - Insulin-Like Growth Factor 1 Receptor Beta Chain
Database Links Reactome: R-HSA-2404192
Reactome: R-HSA-2428928
Reactome: R-HSA-2428933
Reactome: R-HSA-9009391
Cellular Localisation Cell Membrane
Single-Pass Type I Membrane Protein
Alternative Antibody Names Anti-Insulin-Like Growth Factor 1 Receptor antibody
Anti-Insulin-Like Growth Factor I Receptor antibody
Anti-Igf-I Receptor antibody
Anti-Cd Antigen Cd221 Cleaved Into - Insulin-Like Growth Factor 1 Receptor Alpha Chain - Insulin-Like Growth Factor 1 Receptor Beta Chain antibody
Anti-IGF1R antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance